CSPC Pharmaceutical Group (HKG:1093) obtained approval to conduct clinical trials for SYS6041 from China's National Medical Products Administration, a Friday bourse filing said.
The indication for the approval is advanced solid tumors and the drug is expected to be indicated for the treatment of ovarian, endometrial, breast, and non-small cell lung cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.